ASX RELEASE.

emyria
Advanced Therapies | Compassionate Care

19 November 2026

EMYRIA RECRUITS 31 THERAPISTS TO MEET GROWING PATIENT DEMAND

Recruitment designed to meet expected growth in the number of patients treated across Emyria's national Empax network in 2027.

- **31 additional therapists recruited** – Specialised inhouse training commences 27 November 2026, to meet expected growth in the number of patients treated in 2027.
- **18 therapists meet TGA Lead Therapist eligibility criteria –** Expanding the pool of specialised clinicians required to support increased treatment volumes.
- **Includes 10 psychologists** – To meet DVA specific therapist requirements and support anticipated progress in DVA-funded Veteran treatments during 2027.
- **Existing clinics ready to treat more patients** – Therapists allocated across Perth, Brisbane and Sydney, with onboarding commencing CYQ1 2027. Higher utilisation of existing clinics sits alongside continued network growth.

For personal use only

Emyria Limited (ASX: EMD) ("Emyria", or the "Company"), a leader in delivering evidence-based intensive mental-health care, has recruited 31 additional therapists to support increased patient treatment capacity and revenue-generating clinical activity across its national Empax network in preparation for CY27.

The recruitment marks a significant milestone as Emyria moves from establishing its national clinical infrastructure to scaling patient treatment volumes across its network.

Emyria treats people with post-traumatic stress disorder (PTSD) and treatment-resistant depression (TRD) who have not improved with standard care. Each treatment needs trained therapists to be with the patient for multi hour sessions. The number of trained therapists therefore sets the number of patients that Emyria can treat.

The 31 therapists will commence specialised training on 27 November 2026, with progressive onboarding into clinical operations expected from CYQ1 2027, subject to completion of the training and supervised onboarding required to maintain clinical care standards.

Of the 31 recruits, 18 meet the Therapeutic Goods Administration (TGA) Lead Therapist eligibility criteria and 10 are psychologists who will support Veteran treatments funded by the Department of Veterans' Affairs (DVA), expanding Emyria's workforce capability to meet DVA requirements and accommodate anticipated growth in government-funded treatment volumes.

Training will be conducted in Perth. The cohort comprises 22 therapists from Perth, six from Brisbane and three from Sydney. This will bring total trained therapists numbers in excess of 150[1,2].

Preparing to Treat More Patients in 2027

Emyria has invested several years in establishing the specialised clinical infrastructure, workforce training capabilities and treatment protocols required to deliver evidence-based complex mental health treatments in real-world clinical settings.

With its national Empax network established across key Australian markets, the Company expects the number of patients treated to increase in 2027. Improved utilisation of existing clinics will complement continued network growth.

Therapist availability is a key determinant of treatment capacity. Emyria has 18 treatment beds across five sites[3]. Therapist numbers, not beds, limit the number of treatments today. More therapists allows Emyria to treat more patients in these beds without new facility commitments. The recruitment of 31 additional therapists is designed to accommodate this expected growth in 2027, increasing utilisation of established infrastructure as clinicians complete training and supervised onboarding.

The expanded workforce is expected to support increased treatment capacity and associated revenue-generating opportunities across three established areas of Emyria's clinical delivery model:

- **Reimbursed patient treatments –** Increasing the specialised clinical workforce available to deliver Emyria's PTSD and TRD programs across the national Empax network, so that more patients can be treated through established reimbursement pathways.
- **DVA-funded Veteran treatments –** Expanding the pool of psychologists available to meet DVA workforce requirements and support anticipated growth in government-funded treatment volumes for eligible Australian Veterans.
- **Pharmaceutical-sponsored clinical trials –** Strengthening the clinical workforce available to support international pharmaceutical partnerships and sponsor-funded research programs delivered through Emyria's Empax network.

This workforce expansion supports Emyria's strategy to increase patient treatment volumes through 2027 while maintaining the clinical standards, patient safety and treatment outcomes underpinning our care models.

Greg Hutchinson, Emyria Executive Chair, commented:

"Emyria has spent several years establishing the clinical infrastructure, specialist workforce and treatment protocols required to deliver our PTSD and TRD programs at scale. With a national network now established, our priority for 2027 is clear: make our treatments as accessible as possible to those across the country suffering these often otherwise intractable illnesses.

The recruitment of 31 additional therapists is an important step towards unlocking greater treatment capacity across our existing Empax clinics. Every therapist who joins us lets us treat more patients to the same clinical standard. Importantly, the inclusion of 10 psychologists to support DVA-funded Veteran treatments strengthens our ability to respond to anticipated growth in government-funded patient care.

We are now focused on translating our investment in clinical infrastructure into increased patient treatments and, with that, increased commercial activity and revenue. Expanding

For personal use only

our specialised workforce is central to that strategy, supporting reimbursed patient care, Veteran treatments and growing opportunities with international pharmaceutical partners."

References

1) See ASX announcement 20 August 2026
2) See ASX June quarterly activities report 29 July 2026
3) See ASX announcement 29 September 2026


This release has been approved by the Board of Emyria.

For further information, investment opportunities, or more about Emyria's approach to mental health treatment, please contact:

Greg Hutchinson Executive Chair
1300 153 355 | investors@emyria.com

For personal use only

Emyria Limited develops and delivers new treatments for mental health and select neurological conditions through an integrated model of direct clinical services and treatment development:



Emyria Healthcare: Evidence-based treatment for patients not finding relief from conventional care while also helping evaluate emerging new therapies like assisted therapy for PTSD and assisted therapy for treatment-resistant depression.

Emyria Data: Robust and ethically sourced Real-World Data gathered with patients to improve Emyria's unique therapy and drug development programs.

Emyria's Pipeline: New psychedelic-assisted therapies and drug treatments for mental health and select neurological diseases.

For personal use only

EMYRIA'S INTERACTIVE INVESTOR HUB

Investorhub.emyria.com Interact with Emyria's announcements and updates by asking questions and comments, which our team can respond to where possible.

CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

Risks associated with the use of MDMA, MDMA-inspired compounds and psilocybin

All medicines carry risks and specialist prescribers, such as registered psychiatrists, are best placed to assess the suitability of a new medication against a patient's individual circumstances and medical history before proceeding. Adverse effects of MDMA include high blood pressure, increased pulse rate, faintness, and panic attacks, and in some rare cases it can cause loss of consciousness or trigger seizures. Other side effects include involuntary jaw clenching, decreased appetite, restless legs, nausea, headache, sweating and muscle/joint stiffness. Adverse effects of psilocybin can include temporary increase in blood pressure and a raised heart rate. There may be some risk of psychosis in predisposed individuals. The effects of MDMA and psilocybin are unlikely at low doses in the treatment regimens used in psychedelic-assisted psychotherapy while appropriately managed in a controlled environment with direct medical supervision. The risk profile of the MDMA inspired compounds is currently unknown.

The availability of these products is subject to the safety and efficacy of the products being tested through clinical trials. Emyria makes no representations or warranties as to the safety or efficacy of the products or the products' ability (or the ability of its key compounds) to be used in the treatment of indications such as PTSD. There are currently no approved products containing MDMA, psilocybin or MDMA inspired compounds that the TGA has evaluated for quality, safety and efficacy.